In the context of the 37th International Congress on Alzheimer’s Disease – ADI 2026, taking place in Lyon from 14 to 16 April 2026, Sylvie Claeysen was invited to present the findings of the MICMALZ study – Microbiota and Alzheimer’s Disease – on the health programme Mag de la santé on France 5.

The MICMALZ clinical study is a non-interventional study, conducted jointly by the IGF and the Montpellier Memory Resource and Research Centre (CMRR), which aims to identify the microbial signature of Alzheimer’s disease.

Analysis of the samples collected during the study has confirmed that the composition of the microbiota in patients with Alzheimer’s disease differs from that in healthy individuals. The abundance of certain bacterial species increases in association with the disease, whilst others, conversely, are less prevalent in the gut microbiota of Alzheimer’s patients.

Researchers from the Neuroproteomics and Signalling in Brain Disorders team have also shown that the transfer of faecal microbiota (FMT) from Alzheimer’s patients to mice affects the memory of the recipient animals.

These promising initial results, presented at the ADI 2026 conference, pave the way for the identification of microbiota-derived biomarkers, with a view to developing personalised medicine that could involve therapeutic strategies modulating the microbiota using bacterial therapeutics, such as those developed by NBX BIOSCIENCES, a start-up based at the IGF.

To watch the replay: Mag de la santé – 13 avril 2026